ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

vsv-gp BI 1831169

Its studies are led by Boehringer Ingelheim.

Furthest: phase 1, since Dec 10, 20212 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim20 open or runningphase 1since Dec 10, 2021Dec 10, 2021none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 10, 2021First study: phase 1 study in Solid TumorsFirst studyNCT05155332 · 190 enrolled · United States, Australia, Austria and more
  2. Sep 15, 2025Phase 1 study in Solid TumorsNCT07176975 · 46 enrolled · Japan
  3. Nov 10, 2026Primary completion moved from 2027-12-13 to 2028-07-18Date moved laterphase 1 · +7 months · NCT05155332

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07176975Solid Tumors · Japan1SuspendedDec 19, 202846
NCT05155332Solid Tumors · United States, Australia, Austria and more1SuspendedJul 18, 2028190

How it is read

Names in the registry

  • “BI 1831169”, 2 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.